Expert OpinionThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Sikander Ailawadhi, Mayo Clinic, Jacksonville, US, answers the question: Could radiotherapeutic approaches be a promising new treatment option for myeloma?
Dr Ailawadhi discusses the use of radiopharmaceutical agents for the treatment of myeloma, specifically focusing on a novel agent, CLR 131, which is being tested in patients with relapsed/refractory disease. Key takeaways: in the most recent cohort, divided dosing across two days and a second part one week later was able to stop disease progression for 3-3.5 months, in this small patient cohort. Dr Ailawadhi concludes by discussing what setting he believes these agents may be utilized in, noting this may represent an exciting new option for patients with myeloma.
